CMS has finalized its rejection of Epigenomics' blood-based colorectal cancer screening test, depriving the company of the chance to sell the liquid biopsy for Medicare beneficiaries. Epigenomics is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results